LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Cox, Adam
Languages: English
Types: Doctoral thesis
Subjects:
Many cell signalling pathways contribute to prostate cancer (PCa) initiation and survival, but the interplay between them remains poorly understood. In this thesis, conditional transgenic models were employed to investigate the impact of mutating the proto-oncogenes β-catenin, and Kras, and the tumour suppressor gene PTEN, alone and in combination within the murine prostate.\ud β-catenin and Pten single mutants display progression from PIN to invasive adenocarcinoma that appears similar to human Gleason pattern 3. Tumours demonstrate co-activation of the Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways. Kras single mutants develop PIN but do not progress to adenocarcinoma. Double and triple mutants develop more aggressive tumours comparable to Gleason pattern 4. Furthermore, double and triple mutants display upregulated Wnt, PI3K/Akt/mTOR and Ras/MAPK signalling. Expression of p63 negatively correlates with tumour grade, and moreover, progression from PIN to invasive adenocarcinoma is characterised by the synergistic elevation of AR and Ki67, which parallels human PCa.\ud Malignant transformation of a normal prostate epithelial stem cell (PrSC) gives rise to the cancer stem cell (CSC), which may contribute to castrate-resistant PCa. In this study a 3D primary tissue culture assay was optimised to allow maintenance and expansion of prostate cells that display stem-like characteristics in vitro.\ud PrSCs can be isolated by fluorescence activated cell sorting for the antigenic profile Lin-Sca1+CD49f+TropHi, and consistently form spherical structures in Matrigel. PrSCs can withstand multiple round of passage in vitro, and demonstrate the ability to maintain an undifferentiated state. PrSC spheres possess a basal phenotype, supporting a basal location of PrSCs in prostate epithelium.\ud In summary, these mouse models of PCa demonstrate cooperation between important cell signalling pathways in prostate tumourigenesis, and provide a platform for testing novel therapeutics. In addition, the successful isolation and cultivation of cells with stem-like attributes will allow their unique biological properties to be explored further, providing a baseline standard with which to compare the function of CSCs.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • & GLODE, L. M. 2011. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol, 29, 2040-5.
    • DUBROVSKA, A., KIM, S., SALAMONE, R. J., WALKER, J. R., MAIRA, S. M., GARCIA-ECHEVERRIA, C., SCHULTZ, P. G. & REDDY, V. A. 2009. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A, 106, 268- 73.
    • ECKLE, V. S., BUCHMANN, A., BURSCH, W., SCHULTE-HERMANN, R. & SCHWARZ, M. 2004. Immunohistochemical detection of activated caspases in apoptotic hepatocytes in rat liver. Toxicol Pathol, 32, 9-15.
    • EL SEWEDY, T., FORNARO, M. & ALBERTI, S. 1998. Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer, 75, 324-330.
    • ELFIKY, A. A. & JIANG, Z. 2013. kyp. Curr Cancer Drug Targets, 13, 157-64.
    • ENGLISH, H. F., DRAGO, J. R. & SANTEN, R. J. 1985. Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate, 7, 41-51.
    • ENGLISH, H. F., SANTEN, R. J. & ISAACS, J. T. 1987. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate, 11, 229-42.
    • EPSTEIN, J. I. 2010. An update of the Gleason grading system. J Urol, 183, 433-40.
    • EPSTEIN, J. I., ALLSBROOK JR, W. C., AMIN, M. B. & COMMITTEE, I. G. 2005. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma. Am J Surg Pathol, 29, 1228-42.
    • EPSTEIN, J. I., PARTIN, A. W., SAUVAGEOT, J. & WALSH, P. C. 1996. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term followup. Am J Surg Pathol, 20, 286-92.
    • EVANS, G. S. & CHANDLER, J. A. 1987. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate, 11, 339-51.
    • FAHMY, W. E. & BISSADA, N. K. 2003. Cryosurgery for prostate cancer. Arch Androl, 49, 397-407.
    • FAIR, W. R. & CORDONNIER, J. J. 1978. The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol, 120, 695-8.
    • FARNIE, G., CLARKE, R. B., SPENCE, K., PINNOCK, N., BRENNAN, K., ANDERSON, N. G. & BUNDRED, N. J. 2007. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst, 99, 616-27.
    • FAUSTO, N. 2000. Liver regeneration. J Hepatol, 32, 19-31.
    • FEILOTTER, H. E., NAGAI, M. A., BOAG, A. H., ENG, C. & MULLIGAN, L. M. 1998. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene, 16, 1743-8.
    • FISHER, G. H., ET AL. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev, 15, 3249-3262.
    • FONG, D., ET AL. 2008. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer, 99, 1290-1295.
    • FORBES, S. A., BINDAL, N., BAMFORD, S., COLE, C., KOK, C. Y. & BEARE, D., ET AL. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res, 39, D945-50. URL: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/; accessed 26/09/13.
    • FORNARO, M., DELL'ARCIPRETE, R., STELLA, M., BUCCI, C., NUTINI, M., CAPRI, M. G. & ALBERTI, S. 1995. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer. 1995 Sep 4;():. 62, 610-8.
    • FRANCIS, J. C., MCCARTHY, A., THOMSEN, M. K., ASHWORTH, A. & SWAIN, A. 2010. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet, 6, e1000995.
    • SIDDIQUI, J., SAM, L., ANSTETT, M., MEHRA, R., PRENSNER, J. R., PALANISAMY, N., RYSLIK, G. A., VANDIN, F., RAPHAEL, B. J., KUNJU, L. P., RHODES, D. R., PIENTA, K. J., CHINNAIYAN, A. M. & TOMLINS, S. A. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239-43.
    • GREAVES, M. & MALEY, C. C. 2012. Clonal evolution in cancer. Nature, 481, 306-13.
    • GREEN, J. E., GREENBERG, N. M., ASHENDEL, C. L., BARRETT, J. C., BOONE, C., GETZENBERG, R. H., HENKIN, J., MATUSIK, R. J., JANUS, T. J. & SCHER, H. I. 1998. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate, 36, 59-63.
    • GU, G., YUAN, J., WILLS, M. & KASPER, S. 2007. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res, 67, 4807-15.
    • GUERRA, C., MIJIMOLLE, N., DHAWAHIR, A., DUBUS, P., BARRADAS, M., SERRANO, M., CAMPUZANO, V. & BARBACID, M. 2003. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell, 4, 111-20.
    • GUERTIN, D. A. & SABATINI, D. M. 2007. Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
    • GUNIA, S., ALBRECHT, K., KOCH, S., HERRMANN, T., ECKE, T., LOY, V., LINKE, J., SIEGSMUND, M. & MAY, M. 2008. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol, 26, 243-50.
    • GUO, C., LIU, H., ZHANG, B. H., CADANEANU, R. M., MAYLE, A. M. & GARRAWAY, I. P. 2012. Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One, 7, e34219.
    • HAGEN, T. & VIDAL-PUIG, A. 2002. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem Biophys Res Commun, 294, 324-8.
    • HALL, J. A., MAITLAND, N. J., STOWER, M. & LANG, S. H. 2002. Primary prostate stromal cells modulate the morphology and migration of primary prostate epithelial cells in type 1 collagen gels. Cancer Res, 62, 58-62.
    • HALL, J. C. & KILLIAN, G. J. 1987. Changes in rat sperm membrane glycosidase activities and carbohydrate and protein contents associated with epididymal transit. Biol Reprod, 36, 709- 18.
    • HALVORSEN, O. J., HAUKAAS, S. A. & AKSLEN, L. A. 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res, 9, 1474-9.
    • HAN, K. R. & BELLDEGRUN, A. S. 2004. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int, 93, 14-8.
    • HARADA, N., TAMAI, Y., ISHIKAWA, T., SAUER, B., TAKAKU, K., OSHIMA, M. & TAKETO, M. M. 1999. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J, 18, 5931-42.
    • HAYWARD, S. W. & CUNHA, G. R. 2000. The prostate: development and physiology. Radiol Clin North Am, 38, 1-14.
    • HE, T. C., SPARKS, A. B., RAGO, C., HERMEKING, H., ZAWEL, L., DA COSTA, L. T., MORIN, P. J., VOGELSTEIN, B. & KINZLER, K. W. 1998. Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-12.
    • HEIDENREICH, A., BASTIAN, P., BELLMUNT, J., BOLLA, M., JONIAU, S., MASON, M., MATVEEV, V., MOTTET, N., VAN DER KWAST, T., WIEGEL, T. & ZATTONI, F. 2012. Guidelines on Prostate Cancer. European Association of Urology (EAU).
    • HENSLEY, P. J. & KYPRIANOU, N. 2012. Modeling prostate cancer in mice: limitations and opportunities. J Androl, 33, 133-44.
    • HISHA, H., TANAKA, T., KANNO, S., TOKUYAMA, Y., KOMAI, Y., OHE, S., YANAI, H., OMACHI, T. & UENO, H. 2013. Establishment of a novel lingual organoid culture system: generation of organoids having mature keratinized epithelium from adult epithelial stem cells. Sci Rep, 3, 3224.
    • HOCKENBERY, D. M., ZUTTER, M., HICKEY, W., NAHM, M. & KORSMEYER, S. J. 1991. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. PNAS, 88, 6961-5.
    • HOROSZEWICZ, J. S., LEONG, S. S., CHU, T. M., WAJSMAN, Z. L., FRIEDMAN, M., PAPSIDERO, L., KIM, U., CHAI, L. S., KAKATI, S., ARYA, S. K. & SANDBERG, A. A. 1980. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res, 37, 115-332.
    • HORVATH, L. G., HENSHALL, S. M., LEE, C. S., KENCH, J. G., GOLOVSKY, D., BRENNER, P. C., O'NEILL, G. F., KOONER, R., STRICKER, P. D., GRYGIEL, J. J. & SUTHERLAND, R. L. 2005. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer, 113, 415-22.
    • HOU, X., TAN, Y., LI, M., DEY, S. K. & DAS, S. K. 2004. Canonical Wnt signaling is critical to estrogenmediated uterine growth. Mol Endocrinol, 18, 3035-49.
    • HU, H., XIA, S. H., LI, A. D., XU, X., CAI, Y., HAN, Y. L., WEI, F., CHEN, B. S., HUANG, X. P., HAN, Y. S., ZHANG, J. W., ZHANG, X., WU, M. & WANG, M. R. 2002. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer, 102, 580-3.
    • HUANG, H., ET AL. 2005. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res, 11, 4357-4364.
    • HUDSON, D. L., GUY, A. T., FRY, P., O'HARE, M. J., WATT, F. M. & MASTERS, J. R. 2001. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem, 49, 271-8.
    • HUGGINS, C. & HODGES, C. V. Feb 2002. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. J Urol, 167, 948-951, discussion 952.
    • HUGGINS, C., STEVENS, R. E., JR & HODGES, C. V. 1941. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg, 43, 209-23.
    • HURT, E. M., KAWASAKI, B. T., KLARMANN, G. J., THOMAS, S. B. & FARRAR, W. L. 2008. CD44+ CD24(- ) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer, 98, 756-65.
    • IKENOUCHI, J. & UMEDA, M. 2010. FRMD4A regulates epithelial polarity by connecting Arf6 activation with the PAR complex. Proc Natl Acad Sci U S A, 107, 748-53.
    • ISAACS, J. T. & COFFEY, D. S. 1989. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl, 2, 33-50.
    • ISAACS, J. T. & ISAACS, W. B. 2004. Androgen receptor outwits prostate cancer drugs. Nat Med, 10, 26-7.
    • ITTMANN, M., HUANG, J., RADAELLI, E., MARTIN, P., SIGNORETTI, S., SULLIVAN, R., SIMONS, B. W., WARD, J. M., ROBINSON, B. D., CHU, G. C., LODA, M., THOMAS, G., BOROWSKY, A. & CARDIFF, R. D. 2013. Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res, 73, 2718-2736.
    • IWAO, K., NAKAMORI, S., KAMEYAMA, M., IMAOKA, S., KINOSHITA, M., FUKUI, T., ISHIGURO, S., NAKAMURA, Y. & MIYOSHI, Y. 1998. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res, 58, 1021-1026.
    • IYIBOZKURT, A. C., BALCIK, P., BULGURCUOGLU, S., ARSLAN, B. K., ATTAR, R. & ATTAR, E. 2009. Effect of vascular endothelial growth factor on sperm motility and survival. Reprod Biomed Online, 19, 784-8.
    • JAGGUPILLI, A. & ELKORD, E. 2012. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol, 2012, 708036.
    • JANSSEN, K. P., ALBERICI, P., FSIHI, H., GASPAR, C., BREUKEL, C. & FRANKEN, P., ET AL. 2006. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology, 131, 1096-1109.
    • JENSEN, K. B. & WATT, F. M. 2006. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci U S A, 103, 11958-63.
    • JERONIMO, C., BASTIAN, P. J., BJARTELL, A., CARBONE, G. M., CATTO, J. W., CLARK, S. J., HENRIQUE, R., NELSON, W. G. & SHARIAT, S. F. 2011. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol, 60, 753-66.
    • JESIK, C. J., HOLLAND, J. M. & LEE, C. 1982. An anatomic and histologic study of the rat prostate. Prostate, 3, 81-97.
    • JIA, S., LIU, Z. & ZHANG, S. E. A. 2008. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature, 454, 776-9.
    • JIAO, J., HINDOYAN, A., WANG, S., TRAN, L. M., GOLDSTEIN, A. S., LAWSON, D., CHEN, D., LI, Y., GUO, C., ZHANG, B., FAZLI, L., GLEAVE, M., WITTE, O. N., GARRAWAY, I. P. & WU, H. 2012. Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS One, 7, e42564.
    • JOHNSON, M. A., HERNANDEZ, I., WEI, Y. & GREENBERG, N. 2000. Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate. Prostate, 43, 255-62.
    • JONES, P. H., HARPER, S. & WATT, F. M. 1995. Stem cell patterning and fate in human epidermis. Cell, 60, 83-93.
    • JONES, R. G. & THOMPSON, C. B. 2009. Tumour suppressors and cell metabolism: a recipe for cancer growth. Genes Dev, 23, 537-548.
    • JORDAN, C. T., GUZMAN, M. L. & NOBLE, M. 2006. Cancer stem cells. N Engl J Med, 355, 1253-61.
    • KAIGHN, M. E., NARAYAN, K. S., OHNUKI, Y., LECHNER, J. F. & JONES, L. W. 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16-23, 17, 16-23.
    • KALLAKURY, B. V., SHEEHAN, C. E. & ROSS, J. S. 2001. Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol, 32, 849-55.
    • KARANTANOS, T. & THOMPSON, T. C. 2013. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell, 24, 11-3.
    • KARESKOSKI, M. & KATILA, T. 2008. Components of stallion seminal plasma and the effects of seminal plasma on sperm longevity. Anim Reprod Sci, 107, 249-56.
    • KASPER, S. 2005. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem, 94, 279-97.
    • KASPER, S. & MATUSIK, R. J. 2000. Rat probasin: structure and function of an outlier lipocalin. Biochim Biophys Acta, 1482, 249-58.
    • KASPER, S., SHEPPARD, P. C., YAN, Y., PETTIGREW, N., BOROWSKY, A. D., PRINS, G. S., DODD, J. G., DUCKWORTH, M. L. & MATUSIK, R. J. 1998. Development, progression, and androgendependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest, 78, 1-15.
    • KELAVKAR, U. P., PARWANI, A. V., SHAPPELL, S. B. & MARTIN, W. D. 2006. Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia, 8, 510-22.
    • KEOHAVONG, P., DEMICHELE, M. A., MELACRINOS, A. C., LANDRENEAU, R. J., WEYANT, R. J. & SIEGFRIED, J. M. 1996. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res, 2, 411-418.
    • KHOR, L. Y., BAE, K., PAULUS, R., AL-SALEEM, T., HAMMOND, M. E., GRIGNON, D. J., CHE, M., VENKATESAN, V., BYHARDT, R. W., ROTMAN, M., HANKS, G. E., SANDLER, H. M. & POLLACK, A. 2009. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article